MCID: CRV031
MIFTS: 55

Cervical Adenocarcinoma

Categories: Cancer diseases, Reproductive diseases, Rare diseases

Aliases & Classifications for Cervical Adenocarcinoma

MalaCards integrated aliases for Cervical Adenocarcinoma:

Name: Cervical Adenocarcinoma 12 55 51 14 69
Adenocarcinoma of the Uterine Cervix 12
Adenocarcinoma of the Cervix Uteri 55
Adenocarcinoma Cervix Uteri 12
Adenocarcinoma of Cervix 12

Classifications:



External Ids:

Disease Ontology 12 DOID:3702
NCIt 46 C4029
Orphanet 55 ORPHA213772
UMLS via Orphanet 70 C0279672
ICD10 via Orphanet 33 C53.0 C53.1 C53.8
UMLS 69 C0279672

Summaries for Cervical Adenocarcinoma

Disease Ontology : 12 A cervix carcinoma that derives from epithelial cells of glandular origin.

MalaCards based summary : Cervical Adenocarcinoma, also known as adenocarcinoma of the uterine cervix, is related to glassy cell carcinoma of the cervix and adenocarcinoma in situ. An important gene associated with Cervical Adenocarcinoma is CDKN2A (Cyclin Dependent Kinase Inhibitor 2A), and among its related pathways/superpathways are ERK Signaling and Endometrial cancer. The drugs Gardasil and Cisplatin have been mentioned in the context of this disorder. Affiliated tissues include cervix, lymph node and testes, and related phenotypes are cellular and digestive/alimentary

Related Diseases for Cervical Adenocarcinoma

Diseases in the Cervical Adenocarcinoma family:

Early Invasive Cervical Adenocarcinoma

Diseases related to Cervical Adenocarcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 278)
# Related Disease Score Top Affiliating Genes
1 glassy cell carcinoma of the cervix 32.2 ERBB2 ESR1
2 adenocarcinoma in situ 30.5 CDKN1A CDKN2A CDX2 KRT20 KRT7
3 adenocarcinoma 30.3 CDKN1A CDKN2A EGFR ERBB2 PTGS2 TP53
4 adenosquamous carcinoma 30.3 EGFR KRT7 TP53
5 female reproductive endometrioid cancer 30.0 KRT7 TP53
6 suppressor of tumorigenicity 3 30.0 CDKN1A CDKN2A TP53
7 cervical squamous cell carcinoma 29.7 CDKN2A EGFR RASSF1 TP53
8 small cell carcinoma 29.5 EGFR KRT20 KRT7 TP53
9 nasopharyngeal carcinoma 29.4 CDKN2A EGFR RASSF1 TP53
10 renal cell carcinoma, nonpapillary 29.4 EGFR KRT20 KRT7 RASSF1
11 vulval paget's disease 29.3 CDKN2A ERBB2 KRT20 KRT7
12 papilloma 29.2 CDKN1A CDKN2A KRT20 KRT7 TP53
13 squamous cell carcinoma 28.9 CDKN1A CDKN2A EGFR ERBB2 KRT7 PTGS2
14 ovarian cancer 1 28.7 EGFR ERBB2 ESR1 KRT7 TP53
15 endometrial adenocarcinoma 28.4 CDKN2A EGFR ERBB2 ESR1 KRT7 TP53
16 lung cancer 27.4 CDKN1A CDKN2A EGFR ERBB2 KRT20 KRT7
17 early invasive cervical adenocarcinoma 12.1
18 cervicitis 10.8
19 inverted transitional papilloma 10.6 CDKN2A KRT7
20 cystic basal cell carcinoma 10.6 KRT20 KRT7
21 brain stem astrocytic neoplasm 10.5 CDKN2A TP53
22 lung acinar adenocarcinoma 10.5 KRT20 KRT7
23 seminal vesicle adenocarcinoma 10.5 KRT20 KRT7
24 transverse colon cancer 10.5 KRT20 KRT7
25 ovarian large-cell neuroendocrine carcinoma 10.5 KRT20 KRT7
26 squamous cell carcinoma of the oropharynx 10.5 CDKN2A TP53
27 protoplasmic astrocytoma 10.5 PTGS2 TP53
28 eyelid neoplasm 10.5 KRT20 KRT7
29 bowenoid papulosis 10.5 CDKN2A PTGS2
30 malignant syringoma 10.5 KRT20 KRT7
31 krukenberg carcinoma 10.5 KRT20 KRT7
32 spitz nevus 10.5 CDKN2A TP53
33 large intestine adenocarcinoma 10.5 KRT20 KRT7
34 linitis plastica 10.5 KRT20 KRT7
35 small cell carcinoma of the bladder 10.5 KRT20 KRT7
36 malignant peritoneal mesothelioma 10.5 CDKN2A EGFR
37 malignant spiradenoma 10.5 KRT7 TP53
38 benign breast adenomyoepithelioma 10.5 EGFR KRT7
39 keratinizing squamous cell carcinoma 10.5 CDKN2A TP53
40 brain ependymoma 10.5 EGFR TP53
41 adenoid squamous cell carcinoma 10.5 KRT20 KRT7
42 bile reflux 10.4 CDX2 PTGS2
43 vulvar intraepithelial neoplasia 10.4 KRT7 TP53
44 vestibular gland benign neoplasm 10.4 ESR1 TP53
45 bladder papillary transitional cell neoplasm 10.4 KRT20 TP53
46 endometrial clear cell adenocarcinoma 10.4 ESR1 TP53
47 anal canal adenocarcinoma 10.4 CDX2 KRT7
48 bartholin's gland adenoma 10.4 ESR1 TP53
49 urinary tract papillary transitional cell benign neoplasm 10.4 KRT20 TP53
50 anaplastic oligodendroglioma 10.4 CDKN2A EGFR

Graphical network of the top 20 diseases related to Cervical Adenocarcinoma:



Diseases related to Cervical Adenocarcinoma

Symptoms & Phenotypes for Cervical Adenocarcinoma

MGI Mouse Phenotypes related to Cervical Adenocarcinoma:

43 (show all 17)
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.3 KRT7 ERBB2 LAMC2 PTGS2 ESR1 RASSF1
2 digestive/alimentary MP:0005381 10.25 ERBB2 LAMC2 PTGS2 ESR1 RASSF1 TP53
3 homeostasis/metabolism MP:0005376 10.25 ESR1 KRT7 ERBB2 PTGS2 VIL1 RASSF1
4 cardiovascular system MP:0005385 10.22 PTGS2 ESR1 ERBB2 RASSF1 TP53 CDX2
5 endocrine/exocrine gland MP:0005379 10.18 ERBB2 PTGS2 ESR1 RASSF1 TP53 CDKN1A
6 immune system MP:0005387 10.15 EGFR ESR1 LAMC2 TP53 PTGS2 RASSF1
7 embryo MP:0005380 10.14 ERBB2 PTGS2 ESR1 TP53 CDKN1A CDX2
8 integument MP:0010771 10.08 ERBB2 LAMC2 PTGS2 ESR1 TP53 CDKN1A
9 neoplasm MP:0002006 10.02 ERBB2 PTGS2 ESR1 RASSF1 TP53 EGFR
10 limbs/digits/tail MP:0005371 10 ERBB2 LAMC2 ESR1 TP53 CDKN1A CDX2
11 liver/biliary system MP:0005370 9.98 PTGS2 ESR1 RASSF1 TP53 CDKN1A EGFR
12 muscle MP:0005369 9.95 EGFR ESR1 ERBB2 TP53 PTGS2 CDKN1A
13 normal MP:0002873 9.92 ESR1 ERBB2 PTGS2 VIL1 RASSF1 TP53
14 renal/urinary system MP:0005367 9.8 ESR1 KRT7 LAMC2 PTGS2 TP53 CDKN1A
15 reproductive system MP:0005389 9.76 EGFR ESR1 ERBB2 TP53 PTGS2 CDX2
16 respiratory system MP:0005388 9.56 ERBB2 LAMC2 PTGS2 ESR1 TP53 EGFR
17 skeleton MP:0005390 9.28 ERBB2 LAMC2 PTGS2 ESR1 TP53 CDKN1A

Drugs & Therapeutics for Cervical Adenocarcinoma

FDA approved drugs:

# Drug Name Active Ingredient(s) 17 Company Approval Date
1
Gardasil 17 45 quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine Merck June 2006

Drugs for Cervical Adenocarcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 107)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Cisplatin Approved Phase 4,Phase 3,Phase 2,Phase 1 15663-27-1 2767 441203 84093
2 Epoetin alfa Phase 4,Phase 3 113427-24-0
3 Hematinics Phase 4,Phase 3
4
Paclitaxel Approved, Vet_approved Phase 3,Phase 2,Phase 1 33069-62-4 36314
5
Carboplatin Approved Phase 3,Phase 2,Phase 1 41575-94-4 10339178 38904 498142
6
Bevacizumab Approved, Investigational Phase 3,Phase 2 216974-75-3
7
Topotecan Approved, Investigational Phase 3,Phase 2,Phase 1 119413-54-6, 123948-87-8 60700
8
Gemcitabine Approved Phase 3,Phase 2,Phase 1 95058-81-4 60750
9
Vinblastine Approved Phase 3 865-21-4 241903 13342
10
Vinorelbine Approved, Investigational Phase 3 71486-22-1 44424639 60780
11
Bleomycin Approved, Investigational Phase 3 11056-06-7 5360373
12
Fluorouracil Approved Phase 3,Phase 1,Phase 2 51-21-8 3385
13
Ifosfamide Approved Phase 3 3778-73-2 3690
14
Methotrexate Approved Phase 3 1959-05-2, 59-05-2 126941
15
Vindesine Approved, Investigational Phase 3 53643-48-4, 59917-39-4 40839
16
Folic Acid Approved, Nutraceutical, Vet_approved Phase 3,Phase 2 59-30-3 6037
17
leucovorin Approved, Nutraceutical Phase 3,Phase 2 58-05-9 143 6006
18
Tirapazamine Investigational Phase 3,Phase 1 27314-97-2
19 Albumin-Bound Paclitaxel Phase 3,Phase 2,Phase 1
20 Antibodies Phase 3,Phase 2,Phase 1
21 Antibodies, Monoclonal Phase 3,Phase 2,Phase 1
22 Antimitotic Agents Phase 3,Phase 2,Phase 1
23 Antineoplastic Agents, Phytogenic Phase 3,Phase 2,Phase 1
24 Immunoglobulins Phase 3,Phase 2,Phase 1
25 Anti-Infective Agents Phase 3,Phase 2,Phase 1
26 Antiviral Agents Phase 3,Phase 2,Phase 1
27 Angiogenesis Inhibitors Phase 3,Phase 2
28 Angiogenesis Modulating Agents Phase 3,Phase 2
29 Endothelial Growth Factors Phase 3,Phase 2
30 Mitogens Phase 3,Phase 2
31 topoisomerase I inhibitors Phase 3,Phase 2,Phase 1
32 Topoisomerase Inhibitors Phase 3,Phase 2,Phase 1
33 Antimetabolites Phase 3,Phase 2,Phase 1
34 Antimetabolites, Antineoplastic Phase 3,Phase 2,Phase 1
35 Immunosuppressive Agents Phase 3,Phase 2,Phase 1
36 Alkylating Agents Phase 3,Phase 2
37 Anti-Bacterial Agents Phase 3,Phase 2
38 Antibiotics, Antitubercular Phase 3,Phase 2
39 Antirheumatic Agents Phase 3,Phase 1,Phase 2
40 Dermatologic Agents Phase 3
41 Folic Acid Antagonists Phase 3,Phase 2
42 Isophosphamide mustard Phase 3 0
43 Mitomycins Phase 3
44 Nucleic Acid Synthesis Inhibitors Phase 3,Phase 2
45 Vitamin B Complex Phase 3,Phase 2
46 Folate Nutraceutical Phase 3,Phase 2
47 Vitamin B9 Nutraceutical Phase 3,Phase 2
48
Capecitabine Approved, Investigational Phase 2 154361-50-9 60953
49
Imiquimod Approved, Investigational Phase 2 99011-02-6 57469
50
Sunitinib Approved, Investigational Phase 2 341031-54-7, 557795-19-4 5329102

Interventional clinical trials:

(show top 50) (show all 89)

# Name Status NCT ID Phase Drugs
1 Epoetin Beta in Treating Anemia in Patients With Cervical Cancer Completed NCT00046969 Phase 4 cisplatin
2 Paclitaxel and Cisplatin or Topotecan With or Without Bevacizumab in Treating Patients With Stage IVB, Recurrent, or Persistent Cervical Cancer Completed NCT00803062 Phase 3 Cisplatin;Paclitaxel;Topotecan Hydrochloride
3 Comparison of Four Combination Chemotherapy Regimens Using Cisplatin in Treating Patients With Stage IVB, Recurrent, or Persistent Cancer of the Cervix Completed NCT00064077 Phase 3 Cisplatin;Gemcitabine Hydrochloride;Paclitaxel;Topotecan Hydrochloride;Vinorelbine Tartrate
4 Radiation Therapy With or Without Chemotherapy After Surgery in Treating Patients With Stage IB or Stage IIA Cervical Cancer Completed NCT00003209 Phase 3 cisplatin;fluorouracil;ifosfamide;methotrexate;mitomycin C;vinblastine sulfate;vindesine
5 Comparison of Three Chemotherapy Regimens in Treating Patients With Stage IVB, Recurrent, or Persistent Cervical Cancer Completed NCT00003945 Phase 3 cisplatin;topotecan hydrochloride
6 Radiation Therapy and Cisplatin With or Without Epoetin Alfa in Treating Patients With Cervical Cancer and Anemia Completed NCT00017004 Phase 3 Cisplatin
7 Radiation Therapy With or Without Cisplatin or Fluorouracil in Treating Patients With Cancer of the Cervix Completed NCT00003078 Phase 3 cisplatin;fluorouracil
8 Radiation Therapy With or Without Chemotherapy in Patients With Stage I or Stage II Cervical Cancer Who Previously Underwent Surgery Recruiting NCT01101451 Phase 3 Cisplatin
9 Chemotherapy and Pelvic Radiation Therapy With or Without Additional Chemotherapy in Treating Patients With High-Risk Early-Stage Cervical Cancer After Radical Hysterectomy Recruiting NCT00980954 Phase 3 carboplatin;cisplatin;paclitaxel
10 Cisplatin and Radiation Therapy With or Without Carboplatin and Paclitaxel in Patients With Locally Advanced Cervical Cancer Active, not recruiting NCT01414608 Phase 3 Carboplatin;Cisplatin;Paclitaxel
11 Chemotherapy Followed By Surgery Vs Radiotherapy Plus Chemotherapy in Patients With Stage IB or II Cervical Cancer Active, not recruiting NCT00039338 Phase 3 cisplatin
12 Standard Versus Intensity-Modulated Pelvic Radiation Therapy in Treating Patients With Endometrial or Cervical Cancer Active, not recruiting NCT01672892 Phase 3
13 Chemotherapy and Radiation Therapy With or Without Surgery in Treating Patients With Stage I Cancer of the Cervix Terminated NCT00054067 Phase 3 cisplatin
14 Cisplatin and Radiation Therapy With or Without Tirapazamine in Treating Patients With Cervical Cancer Terminated NCT00262821 Phase 3 cisplatin;tirapazamine
15 Cisplatin and Radiation Therapy With or Without Hyperthermia Therapy in Treating Patients With Cervical Cancer Terminated NCT00085631 Phase 3 cisplatin
16 Cisplatin Combined With Radiation Therapy and Hyperthermia in Treating Patients With Stage II, Stage III, or Stage IV Cervical Cancer Unknown status NCT00008112 Phase 2 cisplatin
17 Panitumumab, Cisplatin, and Pelvic Radiation Therapy in Treating Patients With Stage IB, Stage II, or Stage III Cervical Cancer Unknown status NCT01158248 Phase 2 cisplatin
18 Paclitaxel and Carboplatin Followed by Cisplatin and Radiation Therapy in Treating Patients With Stage IB, Stage II, Stage III, or Stage IVA Cervical Cancer Unknown status NCT00462397 Phase 2 carboplatin;cisplatin;paclitaxel
19 Concurrent Treatment of Squamous Cell Carcinoma or Adenocarcinoma of the Cervix With CIGB-300 for Local Application Completed NCT01639625 Phase 2 CIGB300
20 Ixabepilone to Treat Cervical Cancer Completed NCT00924066 Phase 2 Ixempra (Ixabepilone (BMS-247550) )
21 Capecitabine in Treating Patients With Persistent or Recurrent Cervical Cancer Completed NCT00039442 Phase 2 Capecitabine
22 Complete Nerve-Sparing Radical Hysterectomy for Cervical Cancer Completed NCT02562729 Phase 2
23 Phase II Study of HPV Therapeutic Vaccine in HPV Infected Women With Normal Cytology or ASCUS/LSIL Completed NCT01957878 Phase 2
24 Sunitinib Malate in Treating Patients With Uterine Cervical Cancer That is Stage IVB, Recurrent, or Cannot Be Removed By Surgery Completed NCT00389974 Phase 2 sunitinib malate
25 ABI-007 in Treating Patients With Persistent or Recurrent Cervical Cancer Completed NCT00309959 Phase 2 Paclitaxel Albumin-Stabilized Nanoparticle Formulation
26 Pelvic Exenteration in Treating Patients With Recurrent Cervical Cancer Completed NCT00217633 Phase 2
27 Paclitaxel in Treating Patients With Advanced, Refractory, or Recurrent Cervical or Vaginal Cancer Completed NCT00002562 Phase 2 paclitaxel
28 Arsenic Trioxide in Treating Patients With Stage IVB or Recurrent Cervical Cancer Completed NCT00005999 Phase 2 arsenic trioxide
29 Oxaliplatin and Paclitaxel in Treating Patients With Locally Recurrent or Metastatic Cervical Cancer Completed NCT00057863 Phase 2 Paclitaxel;Oxaliplatin
30 Irofulven in Treating Patients With Stage IVB or Recurrent Cervical Cancer Completed NCT00005070 Phase 2 irofulven
31 Interleukin-12 in Treating Patients With Advanced or Recurrent Cancer of the Cervix Completed NCT00003017 Phase 2
32 Surgery and Vaccine Therapy in Treating Patients With Early Cervical Cancer Completed NCT00002916 Phase 2
33 Topotecan and Paclitaxel in Treating Patients With Recurrent or Metastatic Cancer of the Cervix Completed NCT00003065 Phase 2 paclitaxel;topotecan hydrochloride
34 Veliparib, Topotecan Hydrochloride, and Filgrastim or Pegfilgrastim in Treating Patients With Persistent or Recurrent Cervical Cancer Completed NCT01266447 Phase 2 Topotecan Hydrochloride;Veliparib
35 Temsirolimus in Treating Patients With Cervical Cancer That Is Recurrent, Locally Advanced, Metastatic, or Cannot Be Removed By Surgery Completed NCT01026792 Phase 2 Temsirolimus
36 FDG and FMISO PET Hypoxia Evaluation in Cervical Cancer Completed NCT00559377 Phase 2
37 Bevacizumab, Radiation Therapy, and Cisplatin in Treating Patients With Previously Untreated Locally Advanced Cervical Cancer Completed NCT00369122 Phase 2 cisplatin
38 Carboplatin and Paclitaxel With or Without Cediranib Maleate in Treating Patients With Metastatic or Recurrent Cervical Cancer That Cannot Be Removed by Surgery Completed NCT01229930 Phase 2 carboplatin;cediranib maleate;paclitaxel
39 Carboplatin and Topotecan in Treating Patients With Relapsed or Metastatic Cervical Cancer Completed NCT00807079 Phase 1, Phase 2 carboplatin;topotecan hydrochloride
40 Radiation Therapy and Cisplatin With or Without Cetuximab in Treating Patients With Stage IB, Stage II, or Stage IIIB Cervical Cancer Completed NCT00957411 Phase 2 cisplatin
41 Radiation Therapy and Cisplatin With or Without Amifostine for Patients With Stage IIIB or IVA Cervical Cancer Completed NCT00012012 Phase 1, Phase 2 Amifostine trihydrate;Cisplatin
42 Radiation Therapy in Treating Patients With Cervical Cancer Completed NCT00278304 Phase 2
43 Cetuximab and Cisplatin in Treating Patients With Advanced, Persistent, or Recurrent Cervical Cancer Completed NCT00101192 Phase 2 cisplatin
44 Cisplatin and Radiation Therapy in Treating Patients With HIV-Associated Locally Advanced Cervical Cancer Completed NCT01590017 Phase 2 cisplatin
45 Paclitaxel, Topotecan, and Cisplatin in Treating Patients With Advanced, Persistent, or Recurrent Cervical Cancer Completed NCT00276796 Phase 2 cisplatin;paclitaxel;topotecan hydrochloride
46 Intensity-Modulated Radiation Therapy to the Pelvis With or Without Chemotherapy in Treating Patients With Endometrial Cancer or Cervical Cancer That Has Been Removed By Surgery Completed NCT00331760 Phase 2 cisplatin
47 Bryostatin-1 Plus Cisplatin in Treating Patients With Recurrent or Advanced Cancer of the Cervix Completed NCT00005965 Phase 2 bryostatin 1;cisplatin
48 Radiation Therapy Plus Celecoxib, Fluorouracil, and Cisplatin in Patients With Locally Advanced Cervical Cancer Completed NCT00023660 Phase 1, Phase 2 celecoxib;cisplatin;fluorouracil
49 Radiation Therapy Plus Paclitaxel and Cisplatin in Treating Patients With Cervical Cancer Completed NCT00003379 Phase 1, Phase 2 cisplatin;paclitaxel
50 Dose Optimization in 3D Pulsed Dose Rate Brachytherapy for Patients With Locally Advanced Cervical Cancer Recruiting NCT02880007 Phase 2 Cisplatin

Search NIH Clinical Center for Cervical Adenocarcinoma

Genetic Tests for Cervical Adenocarcinoma

Anatomical Context for Cervical Adenocarcinoma

MalaCards organs/tissues related to Cervical Adenocarcinoma:

38
Cervix, Lymph Node, Testes, Endothelial, Liver, Ovary, Colon

Publications for Cervical Adenocarcinoma

Articles related to Cervical Adenocarcinoma:

(show top 50) (show all 330)
# Title Authors Year
1
Ovarian conservation is associated with better survival in young patients with T1N0M0 cervical adenocarcinoma: a population-based study. ( 29362924 )
2018
2
Clinical outcomes of carbon ion radiotherapy with concurrent chemotherapy for locally advanced uterine cervical adenocarcinoma in a phase 1/2 clinical trial (Protocol 1001). ( 29341491 )
2018
3
Uterine cervical adenocarcinoma associated with lobular endocervical glandular hyperplasia: Radiologic-pathologic correlation. ( 29144012 )
2018
4
Growth inhibitory effect of the Src inhibitor dasatinib in combination with anticancer agents on uterine cervical adenocarcinoma cells. ( 29067110 )
2017
5
Comparison of Cold-Knife Conization versus Loop Electrosurgical Excision for Cervical Adenocarcinoma In Situ (ACIS): A Systematic Review and Meta-Analysis. ( 28125627 )
2017
6
Cervical Adenocarcinoma Has a Poorer Prognosis and a Higher Propensity for Distant Recurrence Than Squamous Cell Carcinoma. ( 28604449 )
2017
7
Tumor-associated CD204<sup>+</sup>M2 macrophages are unfavorable prognostic indicators in uterine cervical adenocarcinoma. ( 29274107 )
2017
8
Risk of persistent or recurrent neoplasia in conservatively treated women with cervical adenocarcinoma in situ with negative histological margins. ( 28181670 )
2017
9
Metastatic cervical adenocarcinoma to the orbital subperiosteal space. ( 28457305 )
2017
10
Should ovaries be removed or not in early-stage cervical adenocarcinoma: a multicenter retrospective study of 105 patients. ( 28631536 )
2017
11
Role of positive peritoneal cytology in FIGO stage IB to IIB cervical adenocarcinoma. ( 28186628 )
2017
12
Cervical Adenocarcinoma: Diagnosis of Human Papillomavirus-Positive and Human Papillomavirus-Negative Tumors. ( 28644686 )
2017
13
Increasing incidence of invasive and in situ cervical adenocarcinoma in the Netherlands during 2004-2013. ( 28102052 )
2017
14
Assessment of anti-cancerous potential of 6-gingerol (Tongling White Ginger) and its synergy with drugs on human cervical adenocarcinoma cells. ( 28249781 )
2017
15
Immunohistochemical Expression of the Tumor Suppressor Protein p16INK4a in Cervical Adenocarcinoma. ( 28245508 )
2017
16
Projected impact of HPV vaccination and primary HPV screening on cervical adenocarcinoma: Example from Australia. ( 28720447 )
2017
17
Methods for Measuring and Staging a Uterine Cervical Adenocarcinoma Showing Intracystic Papillary Growth: A Case Report. ( 28700431 )
2017
18
Early-stage node negative cervical adenocarcinoma and squamous cell carcinoma show similar survival outcomes after hysterectomy: a population-based study. ( 29027399 )
2017
19
Excisional treatment in women with cervical adenocarcinoma in situ (AIS): a prospective randomised controlled non-inferiority trial to compare AIS persistence/recurrence after loop electrosurgical excision procedure with cold knife cone biopsy: protocol for a pilot study. ( 28851799 )
2017
20
Isolated port site recurrence of node-negative clinical stage IB1 cervical adenocarcinoma. ( 28331901 )
2017
21
Extrafascial hysterectomy after concurrent chemoradiotherapy in locally advanced cervical adenocarcinoma. ( 27102248 )
2016
22
Cervical Adenocarcinoma: Are We Screening and Treating Patients Appropriately? ( 27529155 )
2016
23
Uterine cervical adenocarcinoma metastasizing concurrently to eutopic and ectopic ovaries: A case report. ( 27005982 )
2016
24
Lack of Significant Effects of Chlamydia trachomatis Infection on Cervical Adenocarcinoma Risk: Nested Case-Control Study. ( 27227411 )
2016
25
Incidence and survival trends of cervical adenocarcinoma in Italy: Cytology screening has become more effective in downstaging the disease but not in detecting its precursors. ( 27639249 )
2016
26
Prevalence of HPV genotypes in cervical adenocarcinoma: a study in Greek women. ( 27569088 )
2016
27
Cytomorphology of Gastric-Type Cervical Adenocarcinoma on a ThinPrep Pap Test: Report of a p16-Positive Tumor Case. ( 27165398 )
2016
28
Preinvasive and Invasive Cervical Adenocarcinoma: Preceding Low-Risk or Negative Pap Result Increases Time to Diagnosis. ( 27977543 )
2016
29
Case images: Cervical adenocarcinoma presenting with a terrible combination: a giant cardiac mass, cardiac tamponade and pulmonary embolism. ( 28045425 )
2016
30
Correlation between EGFR Expression and Radiosensitivity in Cervical Adenocarcinoma Cases. ( 27268625 )
2016
31
Biology and treatment of cervical adenocarcinoma. ( 27198186 )
2016
32
Comment on: Prognostic factors and adjuvant therapy on survival in early-stage cervical adenocarcinoma/adenosquamous carcinoma after primary radical surgery: A Taiwanese Gynecologic Oncology Group (TGOG) study. ( 27793441 )
2016
33
Analysis of the expression and localization of tight junction transmembrane proteins, claudin-1, -4, -7, occludin and JAM-A, in human cervical adenocarcinoma. ( 26847087 )
2016
34
Human Leukocyte Antigen-DR Expression is Significantly Related to an Increased Disease-Free and Disease-Specific Survival in Patients With Cervical Adenocarcinoma. ( 27654088 )
2016
35
Prognostic factors and adjuvant therapy on survival in early-stage cervical adenocarcinoma/adenosquamous carcinoma after primary radical surgery: A Taiwanese Gynecologic Oncology Group (TGOG) study. ( 27566027 )
2016
36
Adjuvant therapy after radical surgery for stage IB-IIB cervical adenocarcinoma with risk factors. ( 27677664 )
2016
37
Cervical adenocarcinoma with stromal micropapillary pattern. ( 26608235 )
2016
38
The variable clinicopathological categories and role of human papillomavirus in cervical adenocarcinoma: A hospital based nation-wide multi-center retrospective study across China. ( 27554015 )
2016
39
Safety of ovarian preservation in women with stage I and II cervical adenocarcinoma: a retrospective study and metaanalysis. ( 27133009 )
2016
40
CIP2A is associated with multidrug resistance in cervical adenocarcinoma by a P-glycoprotein pathway. ( 26404133 )
2015
41
Primary debulking surgery for metastatic cervical adenocarcinoma: A case report. ( 26793767 )
2015
42
Downregulation of phosphoglycerate dehydrogenase inhibits proliferation and enhances cisplatin sensitivity in cervical adenocarcinoma cells by regulating Bcl-2 and caspase-3. ( 25719555 )
2015
43
Prognostic factors affecting cervical adenocarcinoma: 10A years experience in a single institution. ( 25851496 )
2015
44
High levels of soluble MICA are significantly related to increased disease-free and disease-specific survival in patients with cervical adenocarcinoma. ( 25871737 )
2015
45
Clinicopathologic Factors of Cervical Adenocarcinoma Stages IB to IIB. ( 26495760 )
2015
46
Methanolic Extracts from Brown Seaweeds Dictyota cilliolata and Dictyota menstrualis Induce Apoptosis in Human Cervical Adenocarcinoma HeLa Cells. ( 25871374 )
2015
47
Prognostic evaluation of tumor-stroma ratio in patients with early stage cervical adenocarcinoma treated by surgery. ( 26028100 )
2015
48
The complex relationship between human papillomavirus and cervical adenocarcinoma. ( 26334557 )
2015
49
Robot-Assisted Laparoscopic Partial Colpectomy and Intracorporeal Ileal Conduit Urinary Diversion (Bricker) for Cervical Adenocarcinoma Recurrence. ( 26634161 )
2015
50
Comparison of cold knife cone biopsy and loop electrosurgical excision procedure in the management of cervical adenocarcinoma in situ: What is the gold standard? ( 25769659 )
2015

Variations for Cervical Adenocarcinoma

Expression for Cervical Adenocarcinoma

Search GEO for disease gene expression data for Cervical Adenocarcinoma.

Pathways for Cervical Adenocarcinoma

Pathways related to Cervical Adenocarcinoma according to GeneCards Suite gene sharing:

(show all 35)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.71 CDKN1A CDKN2A EGFR ERBB2 ESR1 LAMC2
2
Show member pathways
12.93 CDKN1A CDKN2A EGFR ERBB2 RASSF1 TP53
3
Show member pathways
12.87 CDKN1A EGFR LAMC2 PTGS2 TP53
4
Show member pathways
12.49 CDKN1A EGFR ERBB2 TP53
5
Show member pathways
12.47 CDKN1A CDKN2A CDX2 EGFR ERBB2 ESR1
6
Show member pathways
12.43 CDKN1A CDKN2A EGFR ERBB2 ESR1 TP53
7
Show member pathways
12.37 CDKN1A EGFR ERBB2 TP53
8 12.33 CDKN1A CDKN2A EGFR ERBB2 ESR1 LAMC2
9
Show member pathways
12.22 EGFR ERBB2 ESR1 PTGS2
10 12.18 CDKN1A EGFR ERBB2 ESR1 TP53
11 12.18 CDKN1A CDKN2A EGFR ERBB2 PTGS2 RASSF1
12
Show member pathways
12.11 CDKN1A EGFR ERBB2 TP53
13 12.09 CDKN1A EGFR PTGS2 TP53
14
Show member pathways
11.99 CDKN1A CDKN2A EGFR ERBB2 TP53
15
Show member pathways
11.94 EGFR ERBB2 TP53
16 11.92 EGFR PTGS2 TP53
17 11.91 CDKN1A CDKN2A ERBB2 TP53
18 11.89 CDKN1A PTGS2 TP53
19 11.88 CDKN1A CDKN2A EGFR TP53
20
Show member pathways
11.86 EGFR ERBB2 ESR1
21 11.84 CDKN1A CDKN2A TP53
22 11.81 CDKN1A EGFR ERBB2
23 11.78 CDKN1A LAMC2 PTGS2 TP53
24
Show member pathways
11.76 CDKN1A EGFR ERBB2 ESR1
25 11.62 CDKN1A CDKN2A ERBB2 TP53
26 11.61 CDKN1A EGFR ERBB2
27 11.59 EGFR ERBB2 TP53
28 11.47 CDKN1A PTGS2 TP53
29 11.38 CDKN1A CDKN2A EGFR TP53
30 11.3 CDKN1A EGFR ESR1 PTGS2
31 11.28 ESR1 PTGS2 TP53
32
Show member pathways
11.04 CDKN1A CDKN2A TP53
33 10.96 CDKN1A CDKN2A EGFR ERBB2 RASSF1 TP53
34 10.7 CDKN1A TP53
35
Show member pathways
10.51 CDKN1A TP53

GO Terms for Cervical Adenocarcinoma

Cellular components related to Cervical Adenocarcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein complex GO:0043234 9.1 CDKN1A CDX2 EGFR ESR1 PTGS2 TP53

Biological processes related to Cervical Adenocarcinoma according to GeneCards Suite gene sharing:

(show all 19)
# Name GO ID Score Top Affiliating Genes
1 apoptotic process GO:0006915 9.97 CDKN2A EBAG9 KRT20 TP53 VIL1
2 positive regulation of transcription, DNA-templated GO:0045893 9.91 CDKN2A CDX2 EGFR ESR1 TP53
3 regulation of transcription by RNA polymerase II GO:0006357 9.89 CDKN1A CDX2 EGFR ERBB2 ESR1
4 negative regulation of cell growth GO:0030308 9.75 CDKN1A CDKN2A TP53
5 response to estradiol GO:0032355 9.71 EGFR ESR1 PTGS2
6 wound healing GO:0042060 9.7 EGFR ERBB2 TP53
7 cell cycle arrest GO:0007050 9.62 CDKN1A CDKN2A RASSF1 TP53
8 positive regulation of fibroblast proliferation GO:0048146 9.61 CDKN1A EGFR ESR1
9 response to hyperoxia GO:0055093 9.58 CDKN1A TP53
10 cellular response to heat GO:0034605 9.58 CDKN1A PTGS2 TP53
11 DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediator GO:0006978 9.56 CDKN1A TP53
12 negative regulation of ERBB signaling pathway GO:1901185 9.55 EGFR ERBB2
13 cellular response to epidermal growth factor stimulus GO:0071364 9.54 EGFR ERBB2 VIL1
14 negative regulation of immature T cell proliferation in thymus GO:0033088 9.48 CDKN2A ERBB2
15 signal transduction by p53 class mediator GO:0072331 9.46 CDKN1A TP53
16 response to organic cyclic compound GO:0014070 9.46 CDKN1A EGFR PTGS2 TP53
17 response to organonitrogen compound GO:0010243 9.43 CDKN1A PTGS2 TP53
18 Ras protein signal transduction GO:0007265 9.26 CDKN1A CDKN2A RASSF1 TP53
19 replicative senescence GO:0090399 8.8 CDKN1A CDKN2A TP53

Molecular functions related to Cervical Adenocarcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein phosphatase binding GO:0019903 9.33 EGFR ERBB2 TP53
2 cyclin-dependent protein serine/threonine kinase inhibitor activity GO:0004861 9.32 CDKN1A CDKN2A
3 signal transducer, downstream of receptor, with protein tyrosine kinase activity GO:0004716 9.26 EGFR ERBB2
4 protein kinase binding GO:0019901 9.02 CDKN1A CDKN2A EGFR ESR1 TP53
5 nitric-oxide synthase regulator activity GO:0030235 8.96 EGFR ESR1

Sources for Cervical Adenocarcinoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
27 GO
28 GTR
29 HGMD
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 MedGen
41 MeSH
42 MESH via Orphanet
43 MGI
45 NCI
46 NCIt
47 NDF-RT
50 NINDS
51 Novoseek
53 OMIM
54 OMIM via Orphanet
58 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....